Company Announcements

Director/PDMR Shareholding

Source: RNS
RNS Number : 1140Y
ReNeuron Group plc
02 September 2022
 

ReNeuron Group plc

("ReNeuron" or "the Group")

 

Share Purchase by a Director

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that Iain Ross, Chairman of the Company, has today purchased 100,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

 

Name

Title

Number of Ordinary Shares purchased

Resulting beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Iain Ross

Chairman

100,000

100,000

0.175%

 

                                                                                                                ENDS

 

 

 

Enquiries:

 

ReNeuron

www.reneuron.com/investors

Iain Ross, Chairman

Via Walbrook PR

Catherine Isted, Chief Executive Officer




Liberum Capital Limited (NOMAD and Joint Broker)

Phil Walker (Investment Banking)

Richard Lindley (Investment Banking)

Ben Cryer (Investment Banking)

+44 (0)20 3110 2000

 



Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus

+44 (0)7980 541 893

 

 



 

About ReNeuron

 

ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

 

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 



 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Iain Gladstone Ross

2

Reason for the notification 

a)

Position/status 

Chairman and Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

25.85p

10,000

26.00p

30,000

27.70p

60,000

d)

 

Aggregated information 

100,000 ordinary shares at an average price of 27.005p at a total value of £27,005

e)

Date of the transaction 

02 September 2022

f)

Place of the transaction 

London Stock Exchange AIM Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFIIAIIFIIF